Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells

Leukemia

Volumn 12, Issue 2, 1998, Pages 164-174

  Mustjoki, S ^a   Tapiovaara, H ^a,b   Siren V ^a   Vaheri, A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATL VET AND FOOD RES INSTITUTE   (Finland)

Author keywords

Dexamethasone; Interferons; Plasminogen activation; Promyelocytic leukemia; Retinoids

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; GAMMA INTERFERON; INTERFERON; PLASMIN; PLASMINOGEN; RETINOIC ACID; RNA; UROKINASE; UROKINASE RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; LEUKEMIA CELL; NORTHERN BLOTTING; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RNA ANALYSIS;

EID: 0031884012     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400918     Document Type: Article

References (56)

1. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57: 273-320.
2. Tapiovaara H, Alitalo R, Vaheri A. Plasminogen activation on tumor cell surface and its involvement in human leukemia. Adv Cancer Res 1996; 69: 101-133.
3. Shih GC, Hajjar KA. Plasminogen and plasminogen activator assembly on the human endothelial cell. Proc Soc Exp Biol Med 1993; 202: 258-264.
4. Stoppelli MP, Corti A, Sofficientini A, Cassani G, Blasi F, Assoian RK, Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-4943.
5. Vassalli J-D. The urokinase receptor. Fibrinolysis 1994; 8 (Suppl. 1): 172-181.
6. Danø K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8 (Suppl. 1): 189-203.
7. Biasi F, Conese M, Møller LB, Pedersen N, Cavallaro U, Cubellis MV, Hernandez-Marrero F, Limongi P, Munoz-Canoves P, Resnati M, Riittinen L, Sidenius N, Soravia E, Soria MR, Stoppelli MP, Talarico D, Teesalu T, Valcamonica S. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis 1994; 8 (Suppl. 1): 182-188.
8. Ellis V, Scully MF, Kakkar W. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185-2168.
9. Stephens RW, Pöllänen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen E-M, Rønne E, Behrendt N, Danø K, Vaheri A, Activation of pro-urokinase and plasminogen on human fibrosarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-1995.
10. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
11. Brünner N, Pyke C, Hansen CH, Romer J, Grøndahl-Hansen, Danø K. Urokinase type plnsminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Cancer Treat Res 1994; 71: 299-309.
12. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543-553.
13. Wilson EL, Jacobs P, Dowdle EB. The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood 1983; 61: 568-574.
14. Tapiovaara H, Alitalo R, Stephens RW, Myöhänen H, Ruutu T, Vaheri A, Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood 1993; 82: 914-919.
15. Wada H, Kumeda Y, Ogasawara Z, Ohiwa M, Toshihiro K, Tamaki S, Ohno T, Kageyama S, Kobayashi T, Deguchi K, Shirakawa S. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Hematol 1993; 42: 166-170.
16. Plesner T, Ploug M, Ellis V, Rønne E, Høyer-Hansen G, Wittrup M, Pedersen TL, Tschering T, Danø K, Hansen NE. The receptor fpr urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994; 83: 808-015.
17. Nykjaer A, Møller B, Todd RF III, Christensen T, Andreasen PA, Gliemann J, Petersen CM. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 1994; 152: 505-516.
18. Reiter LS, Spertini O, Kruithof E. Plasminogen activators play an essential role in extracellular-matrix invasion by lymphoblastic T cells. Int J Cancer 1997; 70: 461-466.
19. Akenami F, Sirén V, Koskiniemi M, Siimes MA, Teräväinen H, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 1996; 49: 577-580.
20. Larson RA, Kondo K, Vardiman JW, Butler AE, Golob HM, Rowley JD. Evidence for a 15:17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76: 827-841.
21. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci GP. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25.
22. Casini T, Grignani F, Pelicci GP. Genetics of APL and the molecular basis of retinoic acid treatment. Int J Cancer 1997; 70: 473-474.
23. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux R, Degos L. All-frans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 79: 1704-1709.
24. Warrell RP Jr. Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia. Int J Cancer 1997; 70: 496-497.
25. Dombret H, Scrobohaci ML, Ghorra P, Zini JM, Daniel MT, Castaigne S, Degos L. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-frans retinoic acid treatment. Leukemia 1993; 7: 2-9.
26. Bennett B, Booth NA, Droll A, Dawson AA. The bleeding disorder in APL: fibrinolysis due to uPA rather than defibrination. Br J Haematol 1989; 71: 511-516.
27. Dombret H, Scrobohaci M-L, Daniel M-T, Micléa J-M, Castaigne S, Chomienne C, Fenaux P, Degos L. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-frans retinoic acid (ATRA) therapy. Leukemia 1995; 9: 19-24.
28. Fukao H, Ueshima S, Okada K, Yamamoto K, Matsuo T, Matsuo O. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation. Thromb Res 1992; 68: 57-65.
29. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77: 1949-1957.
30. De Stefano B, Teofili L, Sica S, Mastrangelo A, Di Mario A, Rutella S, Saluteri P, Rumi C, Onofrio G, Leone G. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood 1995; 86: 3535-3541.
31. Stephens RW, Tapiovaara H, Alitalo R, Reisberg T, Lymboussakis A, Myöhänen H, Vaheri A. Cell-surface plasminogen activation and leukemia. Fibrinolysis 1992; 6: 35-39.
32. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.
33. Borden EC. Interferons - expanding therapeutic roles. New Engl J Med 1992; 326: 1491-1493.
34. Lippman SM, Glisson BS, Kavanagh JJ, Lotan R, Hong WK, Paredes-Espinoza M, Hittelman WN, Holdener EE, Krakoff IH. Retinoic acid and Interferon combination studies in human cancer. Eur J Cancer 1993; 29A (Suppl. 5): S9-S13.
35. Lippman SM, Lotan R, Schleuniger U. Retinoid-interferon therapy of solid tumors. Int J Cancer 1997; 70: 481-483.
36. Nason-Burchenal K, Gandini D, Botto M, Allopenna J, Seale J, Cross N, Goldman J, Dmitrovsky E, Pandolfi PP. Interferon augments PML and ML/RARα expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line. Blood 1996; 88: 3926-3936.
37. Tsurugano S, Togawa A, Soda Y, Miwa A, Takaku F, Yuo A, Yamada K, Hirai H. Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all-trans retinoic acid. Rinsho- Ketsueki 1994; 35: 36-41.
38. Koller E, Krieger O, Kasparu H, Lutz D. Restoration of all-trans retinoic acid sensitivity by interferon in acute promyelocytic leukaemia. Lancet 1991; 338: 1154-1155.
39. Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors, Blood 1994; 83: 1883-1891.
40. Lanotte M, Martin-Thouvenin V, Najman S, Ballerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-1086.
41. Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F. Autocrine saturation of prourokinase receptors on human A431 cells. Cell 1986; 45: 675-684.
42. Tapiovaara H, Vaheri A, Alitalo R, Pheng-Siew S, Woodrow G, Stephens RW. Enhanced activation of prourokinase by human RC2A leukemia cells. Semin Thromb Hemostas 1991; 17: 251-261.
43. Deutsch D, Mertz E. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096.
44. Sareneva T, Pirhonen J, Cantell K, Julkunen I. N-glycosylation of human interferon-γ: glycans at Asn-25 are critical for protease resistance. Biochem J 1995; 308: 9-14.
45. Sareneva T, Pirhonen J, Cantell K, Kalkkinen N, Julkunen I. Role of N-glycosylation in the synthesis, dimerization and secretion of human interferon-γ. Biochem J 1994; 303: 831-840.
46. Stephens RW, Leung K-C, Pöllänen J, Salonen E-M, Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Meth 1987; 105: 245-251.
47. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
48. + RNA. Proc Natl Acad Sci USA 1984; 81: 4727-4731.
49. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-474.
50. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type-1 : reactive center and aminoterminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-218.
51. Fort P, Marty L, Piechaczyk M, Sabrouty SE, Dani C, Jeanteur P, Blanchard JM. Various rat adult tissues express only one major mRNA species for the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 1985; 13: 1431-1432.
52. Gianni M, Zanotta S, Terao M, Rambaldi A, Garattini E. Interferons induce normal and aberrant retinoic-acid receptors type α in acute promyelocytic leukemia cells: potentiation of the induction of retinoic-dependent differentiation markers. Int J Cancer 1996; 68: 75-83.
53. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 1996; 88: 114-123.
54. Matikainen S, Tapiovaara H, Vaheri A, Hurme M. Activation of interleukin-1β gene expression during retinoic acid-induced gran- ulocytic differentiation of promyeloid leukemia cells. Cell Growth Differ 1994; 5; 975-982.
55. Gyetko MR, Wilkinson DD, Sitrin RG. Monocyte urokinase expression: modulation by interleukins. J Leuk Biol 1993; 53: 598-601.
56. Lu H, Mirshahi P, Krief C, Soria C, Soria J, Mishal Z, Bertrand JY, Li H, Picot C, Pujade E, Bertnadou A, Caen JP, Parallel induction of fibrinolysis and receptors for plasminogen and urokinase by interfered gamma on U937 cells. Biochem Biophys Res Comm 1988; 155: 418-422.